All In Biotech

Free tool

FAERS Monitor: Sular

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020356 or its brand name (Sular, Nisoldipine). Reports on generic versions are filed under their own applications.

Reports

1,198

Serious

780

65% of reports

Hospitalization

394

Death reported

123

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea89
  • drug ineffective79
  • dizziness77
  • headache76
  • fatigue74
  • renal failure65
  • pain64
  • dyspnoea63
  • asthenia62
  • diarrhoea59
  • anxiety54
  • myocardial infarction54
  • oedema peripheral54
  • hypertension50
  • pruritus50

Reports by year received

View as table
YearReports
200458
200549
200682
200770
200881
2009106
2010111
201183
201285
201340
201454
201555
201651
201745
201858
201965
202028
202121
202215
20239
202415
202510
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,961 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
renal failureSignal658.66.8431
oedema peripheralSignal547.86.0314
myocardial infarctionSignal545.44.2193
hypertensionSignal504.13.2117
anxietySignal543.32.687
astheniaSignal622.92.376
dizzinessSignal772.72.283
pruritusSignal502.31.735
headacheSignal762.11.746
nausea892.01.643
dyspnoea632.01.529
pain641.81.424
fatigue741.71.320
diarrhoea591.61.313
drug ineffective791.10.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.